AMENDMENT TO THE CLAIMS: This listing of claims replaces all prior versions and listings of claims in the instant patent application. Claims 1, 47, 70, 71 and 92 are amended, claims 9-21, 26-32, 34-36, 45, 46, 55-63, 68, 69, 72-76, 78-80, 89 and 90 are canceled and new claims 116-121 are added herein.

Listing of claims:

1. (Currently Amended) A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding HIF1α (SEQ ID NO: 133), wherein said compound comprises at least an 8-nucleobase portion of SEQ ID NO: 189 or 446, and wherein said compound specifically hybridizes with said nucleic acid molecule encoding HIF1α and inhibits the expression of HIF1α.

2. (Original) The compound of claim 1 comprising 12 to 50 nucleobases in length.

3. (Original) The compound of claim 2 comprising 15 to 30 nucleobases in length.

4. (Original) The compound of claim 1 comprising an oligonucleotide.

5. (Original) The compound of claim 4 comprising an antisense oligonucleotide.

6. (Original) The compound of claim 4 comprising a DNA oligonucleotide.

7. (Original) The compound of claim 4 comprising an RNA oligonucleotide.

8. (Original) The compound of claim 4 comprising a chimeric oligonucleotide.

9-21. (Canceled)

22. (Original) The compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.

23. (Original) The compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety.

24. (Original) The compound of claim 1 having at least one phosphorothioate internucleoside linkage.

25. (Original) The compound of claim 1 having at least one 5-methylcytosine.

26-32. (Canceled)

33. (Original) A method of inhibiting the expression of HIF1α in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of HIF1α is inhibited.

34-36. (Canceled)

37. (Original) A kit or assay device comprising the compound of claim 1.

38. (Original) A method of treating an animal having a disease or condition associated with HIF1α comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of HIF1α is inhibited.

39. (Original) The method of claim 38 wherein the disease or condition is a hyperproliferative disorder.

40. (Original) The method of claim 39 wherein the hyperproliferative disorder is cancer.

41. (Original) The method of claim 40 wherein the cancer carries a p53 mutation.

42. (Original) The method of claim 39 wherein the hyperproliferative disorder is an angiogenic disorder.

43. (Original) The method of claim 42 wherein the angiogenic disorder affects the eye.

44. (Original) A composition comprising the compound of claim 1 in a pharmaceutically acceptable carrier.

45-46. (Canceled)

47. (Currently Amended) A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding HIF2α (SEQ ID NO: 212), wherein said compound specifically hybridizes with said nucleic acid molecule encoding HIF2α and inhibits the expression of HIF2α.

48. (Original) The compound of claim 47 comprising 12 to 50 nucleobases in length.

49. (Original) The compound of claim 48 comprising 15 to 30 nucleobases in length.

50. (Original) The compound of claim 47 comprising an oligonucleotide.

51. (Original) The compound of claim 50 comprising an antisense oligonucleotide.

52. (Original) The compound of claim 50 comprising a DNA oligonucleotide.

53. (Original) The compound of claim 50 comprising an RNA oligonucleotide.

54. (Original) The compound of claim 50 comprising a chimeric oligonucleotide.

55-63. (Canceled)

64. (Original) The compound of claim 47 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.

65. (Original) The compound of claim 47 having at least one 2'-O-methoxyethyl sugar moiety.

66. (Original) The compound of claim 47 having at least one phosphorothioate internucleoside linkage.

67. (Original) The compound of claim 47 having at least one 5-methylcytosine.

68-69. (Canceled)

70. (Currently Amended) The compound of claim 47 comprising at least an 8-nucleobase portion of SEQ ID NO: ~~260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,~~ 285~~, 286, 287, 288, 289, 290, 291, 292, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 305, 306, 307, 308, 309, 310, 311, 313, 314, 315, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 331, 332, 333, 334 or 335~~.

71. (Currently Amended) The compound of claim 47 having a sequence ~~selected from the group~~ consisting of ~~SEQ ID NO, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,~~ SEQ ID NO: 285~~, 286, 287, 288, 289, 290, 291, 292, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 305, 306, 307, 308, 309, 310, 311, 313, 314, 315, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 331, 332, 333, 334 and 335~~.

72-76. (Canceled)

77. (Original) A method of inhibiting the expression of HIF2α in cells or tissues comprising contacting said cells or tissues with the compound of claim 47 so that expression of HIF2α is inhibited.

78-80. (Canceled)

81. (Original) A kit or assay device comprising the compound of claim 47.

82. (Original) A method of treating an animal having a disease or condition associated with HIF2α comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 47 so that expression of HIF2α is inhibited.

83. (Original) The method of claim 82 wherein the disease or condition is a hyperproliferative disorder.

84. (Original) The method of claim 83 wherein the hyperproliferative disorder is cancer.

85. (Original) The method of claim 84 wherein the cancer carries a p53 mutation.

86. (Original) The method of claim 83 wherein the hyperproliferative disorder is an angiogenic disorder.

87. (Original) The method of claim 86 wherein the angiogenic disorder affects the eye.

88. (Original) A composition comprising the compound of claim 47 in a pharmaceutically acceptable carrier.

89-90. (Canceled)

91. (Original) An antisense compound which inhibits the expression of HIF1α and HIF2α.

92. (Currently Amended) The antisense compound of claim 91 comprising SEQ ID NO: ~~443, 444, 233,~~ 141, 445, 446, ~~447, 448, 449 or~~ 449, 450, 451 or 452.

93. (Original) The antisense compound of claim 91 which comprises at least one universal base.

94. (Original) The antisense compound of claim 93 wherein the universal base is inosine or 3-nitropyrrole.

95. (Original) A composition comprising the compound of claim 91 and a pharmaceutically acceptable carrier.

96. (Original) A method of inhibiting the expression of HIF1α and HIF2α in cells or tissues comprising contacting said cells or tissues with the compound of claim 91 so that expression of HIF1α and HIF2α is inhibited.

97. (Original) A method of inhibiting the expression of HIF1α and HIF2α in cells or tissues comprising contacting said cells or tissues with (i) a first compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding HIF1α, wherein said first compound specifically hybridizes with said nucleic acid molecule encoding HIF1α and

inhibits expression of HIF1α, and (ii) a second compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding HIF2α, wherein said second compound specifically hybridizes with said nucleic acid molecule encoding HIF2α and inhibits expression of HIF2α, so that expression of HIF1α and HIF2α is inhibited.

98. (Original) A method of modulating hypoxia-inducible gene expression in cells or tissues comprising contacting said cells or tissues with (i) a first compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding HIF1α, wherein said first compound specifically hybridizes with said nucleic acid molecule encoding HIF1α and inhibits expression of HIF1α, and (ii) a second compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding HIF2α, wherein said second compound specifically hybridizes with said nucleic acid molecule encoding HIF2α and inhibits expression of HIF2α, so that expression of HIF1α and HIF2α is inhibited.

99. (Original) The method of claim 98 wherein said cells or tissues are cancer cells or tissues.

100. (Original) The method of claim 99 wherein the cancer cells or tissues carry a p53 mutation.

101. (Original) A method of modulating hypoxia-inducible gene expression in cells or tissues comprising contacting said cells or tissues with a compound of claim 91 so that expression of HIF1α and HIF2α is inhibited.

102. (Original) The method of claim 101 wherein said cells or tissues are cancer cells or tissues.

103. (Original) The method of claim 102 wherein the cancer cells or tissues carry a p53 mutation.

104. (Original) A method of treating an animal having a disease or condition associated with hypoxia or a hypoxia-inducible factor or a hypoxia inducible gene comprising administering to said animal (i) a therapeutically or prophylactically effective amount of a first compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding HIF1α, wherein said first compound specifically hybridizes with said nucleic acid molecule

encoding HIF1α and inhibits expression of HIF1α, and (ii) a therapeutically or prophylactically effective amount of a second compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding HIF2α, wherein said second compound specifically hybridizes with said nucleic acid molecule encoding HIF2α and inhibits expression of HIF2α, so that expression of HIF1α and HIF2α is inhibited.

105. (Original) The method of claim 104 wherein the disease or condition is a hyperproliferative disorder.

106. (Original) The method of claim 105 wherein the hyperproliferative disorder is cancer.

107. (Original) The method of claim 106 wherein the cancer carries a p53 mutation.

108. (Original) The method of claim 105 wherein the hyperproliferative disorder is an angiogenic disorder.

109. (Original) The method of claim 108 wherein the angiogenic disorder affects the eye.

110. (Original) A method of treating an animal having a disease or condition associated with hypoxia or a hypoxia-inducible factor or a hypoxia inducible gene comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of claim 91 so that expression of HIF1α and HIF2α is inhibited.

111. (Original) The method of claim 110 wherein the disease or condition is a hyperproliferative disorder.

112. (Original) The method of claim 111 wherein the hyperproliferative disorder is cancer.

113. (Original) The method of claim 112 wherein the cancer carries a p53 mutation.

114. (Original) The method of claim 111 wherein the hyperproliferative disorder is an angiogenic disorder.

115. (Original) The method of claim 114 wherein the angiogenic disorder affects the eye.

116. (New) The compound of claim 1, comprising at least an 8-nucleobase portion of SEQ ID NO: 189.

117. (New) The compound of claim 116 consisting of SEQ ID NO: 189.

118. (New) The compound of claim 1, comprising at least an 8-nucleobase portion of SEQ ID NO: 446.

119. (New) The compound of claim 118 consisting of SEQ ID NO: 446.

120. (New) The compound of claim 1 having 100% complementarity with the nucleic acid molecule encoding HIF1α.

121. (New) The compound of claim 47 having 100% complementarity with the nucleic acid molecule encoding HIF2α.